Qiagen's Experience Developing KRAS CDx for Erbitux Yields Lessons for Rx/Dx Development | GenomeWeb

Originally published Nov. 16.

BOSTON – Although Qiagen is now a key diagnostic development partner for pharma companies looking to advance personalized treatments, the firm's road to launching its first companion test earlier this year wasn't without its perils. In light of this, Qiagen's experience commercializing the diagnostic, a KRAS test to identify best responders to the colorectal cancer drug Erbitux, offers valuable lessons for future personalized medicine collaborations between drug and diagnostic firms, according to a company official.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.